# RMC-9805

| | |
|---|---|
| **Cat. No.:** | HY-156819 |
| **CAS No.:** | 2922732-54-3 |
| **Molecular Formula:** | $C_{63}H_{88}F_3N_{11}O_7$ |
| **Molecular Weight:** | 1168.44 |
| **Target:** | Ras |
| **Pathway:** | GPCR/G Protein; MAPK/ERK Pathway |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 125 mg/mL (106.98 mM; Need ultrasonic)

**Preparing Stock Solutions**

| Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 0.8558 mL | 4.2792 mL | 8.5584 mL |
| 5 mM | 0.1712 mL | 0.8558 mL | 1.7117 mL |
| 10 mM | 0.0856 mL | 0.4279 mL | 0.8558 mL |

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

**Description**

RMC-9805 (KRAS G12D inhibitor 18) is a KRAS G12D inhibitor[1]. RMC-9805 is orally active. RMC-9805 inhibits RAS signaling and induces apoptosis in KRAS G12D mutant cancer cells[2].

**$IC_{50}$ & Target**

KRAS(G12D)

## REFERENCES

[1]. BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13

[2]. Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement): 3475

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA